Wednesday, October 11, 2017 8:36:34 AM
Posted October 10, 2017 05:21 pm - Updated October 11, 2017 12:06 am
By Tom Corwin Staff Writer, The Augusta Chronicle
As the U.S. begins its annual flu season, experts warn that the country is ill-prepared for a pandemic flu that could cause widespread disruption and death.
In a webinar Tuesday with the Association of Health Care Journalists, flu experts outlined potential problems that will occur if and when there is another flu pandemic. Those occur when there is a large mutation in the current circulating flu viruses that it is unlike previous strains or the emergence of a wholly new kind of strain, often from one that jumps from animals like chickens or pigs to humans, said Dr. Sonja Olsen, deputy chief of the Epidemiology and Prevention Branch in the Flu Division at the Centers for Disease Control and Prevention.
Since 2013, the CDC has been monitoring an avian influenza strain called H7N9 that has caused some human infections, increasing from 135 cases to 759 in the last season that ended in August. About 70 percent of those patients ended up in intensive care units and 40 percent died, she said. However, the virus has not shown yet it can pass very well from human to human, Olsen said.
In an analysis published in recent months, scientists looked carefully at the virus strain and tried to see if it could be made to create certain mutations that would make it more adaptable to humans, known as “gain of function” studies, she said. They noted that it already had some mutations similar to strains that caused pandemics in 1957 and 1968. And that with a few small changes, it could adapt to attack human cells that line the airway, Olsen said.
It “required only a small amount of change to potentially be more devastating in humans,” she said.
The problem with preparing for a pandemic is not so much in the U.S. as it is with other countries whose infrastructure and public health may not be as robust. That is a problem because of the global nature of trade and in particular our reliance on other countries to supply essential drugs and supplies, said Dr. Michael Osterholm, director of the Center for Infectious Disease Research and Policy at the University of Minnesota.
They looked at 30 essential drugs and found that they all are made outside the U.S. except for a couple made in Puerto Rico. Any kind of disruption from a pandemic elsewhere, particularly in India or China, would have a rapid impact on U.S. health care, he said. This is already happening with the devastation in Puerto Rico, which manufactures some drugs for the U.S. already in short supply now, he said. Nor is the U.S. government ready itself to deal with a pandemic, Osterholm said.
“This administration does not have a team in place to deal with that, in my estimation,” he said, though in fairness neither did President Obama. “This is going to take a big team.”
“There are lots of gaps globally,” Olsen said.
Reach Tom Corwin at (706) 823-3213 or tom.corwin@augustachronicle.com
http://chronicle.augusta.com/news/2017-10-10/us-not-prepared-flu-pandemic-experts-warn
1/2 cent Vancouver penny mooching pirates!
Recent BVXV News
- Form NT 20-F - Notification of inability to timely file Form 20-F • Edgar (US Regulatory) • 04/30/2024 08:06:46 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/16/2024 09:27:06 PM
- Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMG • PR Newswire (US) • 04/10/2024 11:00:00 AM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 03/12/2024 08:17:13 PM
- Scinai leadership to attend BIO-Europe Spring 2024 • PR Newswire (US) • 03/12/2024 12:00:00 PM
- Scinai Welcomes Liat Halpert as Head of Business Development and Sales • PR Newswire (US) • 02/13/2024 12:00:00 PM
- Scinai Immunotherapeutics Announces Closing of Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds • PR Newswire (US) • 01/04/2024 09:01:00 PM
- Scinai Immunotherapeutics Regains Compliance with Nasdaq's Stockholders' Equity Rule • PR Newswire (US) • 11/20/2023 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 09/07/2023 09:27:02 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/06/2023 04:01:30 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/06/2023 03:44:03 PM
- BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics • GlobeNewswire Inc. • 09/06/2023 10:00:00 AM
- Form 424B2 - Prospectus [Rule 424(b)(2)] • Edgar (US Regulatory) • 08/28/2023 08:01:36 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/28/2023 04:15:26 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/24/2023 08:05:06 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/23/2023 10:10:14 AM
- Form F-3 - Registration statement by foreign private issuers • Edgar (US Regulatory) • 08/18/2023 08:16:19 PM
- Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend] • Edgar (US Regulatory) • 08/18/2023 02:07:35 PM
- Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend] • Edgar (US Regulatory) • 08/14/2023 10:08:59 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/11/2023 01:44:48 PM
- BiondVax Reports Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/11/2023 01:00:00 PM
- Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules • GlobeNewswire Inc. • 08/01/2023 08:01:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/01/2023 08:00:04 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/12/2023 07:10:31 PM
- IBN Announces Latest Episode of The Bell2Bell Podcast featuring Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd. • GlobeNewswire Inc. • 07/11/2023 12:17:00 PM
FEATURED Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • May 8, 2024 9:05 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM